The introduction of nicotinamide as a nicotine substitution in e-cigarette and smokeless products and solutions represents a big regulatory challenge to the FDA. Nicotinamide does not have nicotinic receptor agonist action and is understood to work as a sedative at higher dosages6. The promises created by Nicotine River, ECBlend, and other distribu